G1 Therapeutics, Inc. (GTHX)

Market Cap	378.17M
Revenue (ttm)	58.20M
Net Income (ttm)	-44.77M
Shares Out	52.89M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,251,945
Open	7.15
Previous Close	7.15
Day's Range	7.14 - 7.16
52-Week Range	1.08 - 7.19
Beta	1.68
Analysts	Buy
Price Target	3.50 (-51.05%)
Earnings Date	Oct 30, 2024

About GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2017
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: GTHX
• Website: https://www.g1therapeutics.com

Financial Performance

In 2023, G1 Therapeutics's revenue was $82.51 million, an increase of 60.84% compared to the previous year's $51.30 million. Losses were -$47.97 million, -67.49% less than in 2022.

Analyst Summary

According to 4 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price target is $3.5, which is a decrease of -51.05% from the latest price.

Price Target

$3.5

(-51.05% downside)

Analyst Consensus: Buy